All

Dr Mary Canning has been Recognised as a Leader in UK Life Sciences

CAMBRIDGE, UK – 10 NOVEMBER 2020. Released today by BioBeat, the seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders in the UK bioscience sector. The UK life sciences sector has risen to the challenges posed by COVID-19 with exceptional…

Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting

Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH) New analyses from the Phase 3 PEGASUS head-to-head study demonstrate greater treatment response and quality–of–life improvements with pegcetacoplan versus eculizumab, a C5 inhibitor Using a matching-adjusted indirect comparison (MAIC), improvements in clinical, hematological and…

Epidarex Capital Portfolio Company SIRAKOSS Acquired by OSSDSIGN

Second significant value realisation this quarter highlights Epidarex’s successful approach to life science investing Bethesda, MD, USA, and Edinburgh, UK; November 3rd, 2020 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, is pleased to announce its second value realisation this quarter with the…

Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)

Post hoc analysis of Phase 2 FILLY study shows 39% reduction in rate of progression from nascent GA, an earlier form of disease, to GA in patients treated with pegcetacoplan monthly vs. sham First ever observation of slowed nascent GA progression in a Phase 2 study signals potential benefit of earlier intervention with pegcetacoplan in patients with GA Data support hypothesis that targeting C3 with pegcetacoplan addresses an underlying cause of disease,…